TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
VNDA

Vanda Pharmaceuticals Inc

Healthcare · Biotechnology

4.60$ +0.9% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

Vanda Pharmaceuticals Inc (VNDA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 412 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet VNDA
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
208 210 205 211 206 205 317 303 312 332 351 372 474 484 489 507 516 533 543 568 580 594 604 609 622 634 645 642 642 648 653 651 645 656 632 625 601 489 434 412
170 174 169 175 170 170 282 269 279 299 306 316 280 354 361 381 390 409 421 447 462 478 492 497 507 519 534 534 537 433 439 439 432 439 408 395 367 347 293 264
33 40 20 14 23 34 155 61 61 61 34 47 39 45 65 95 57 61 72 57 51 52 67 58 49 135 354 150 183 136 125 103 100 102 112 81 70 85 54 56
143 141 138 137 140 143 249 231 241 257 268 280 238 312 312 340 349 368 378 396 406 433 435 441 455 467 501 489 490 388 394 388 376 375 341 326 294 264 202 170
16 20 18 21 18 18 23 25 25 29 26 24 27 26 29 25 28 30 31 37 41 32 30 29 29 34 25 34 29 34 37 42 43 47 45 45 51 55 57 60
0.9 0.8 0.8 0.7 0.9 0.8 1.0 1.2 0.9 1.0 1.1 1.1 1.0 1.1 1.3 1.4 1.3 1.3 1.4 1.1 0.9 1.0 1.3 1.5 1.6 1.2 1.1 1.1 1.0 1.4 1.5 1.5 1.6 1.7 1.9 2.2 2.0 1.9 1.7 1.7
4.7 5.0 5.5 5.7 5.4 5.3 5.1 4.8 4.6 4.4 4.3 4.2 4.2 3.9 3.9 3.7 3.9 4.1 3.8 14 13 12 2.9 11 2.6 2.6 2.3 2.2 – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
30 28 27 27 27 26 26 25 25 25 24 24 23 23 23 22 22 22 21 21 20 20 20 19 19 19 18 18 17 121 119 118 116 114 112 111 109 117 115 113
79 79 77 79 75 74 76 52 51 57 73 76 74 73 72 75 75 80 76 86 86 89 101 101 106 107 109 102 99 104 109 109 104 118 121 138 135 162 153 192
51 50 73 75 72 70 72 47 46 53 59 63 60 60 59 62 61 66 62 72 72 74 91 88 93 91 94 87 85 88 93 94 89 100 104 121 118 145 136 164
25 – 25 25 27 27 27 – – – 2.2 2.3 2.1 2.1 2.1 2.2 2.0 2.1 2.1 2.1 2.3 2.3 2.3 2.2 2.2 2.3 2.3 2.4 2.4 2.4 2.4 2.4 2.5 4.3 4.4 4.7 4.7 5.6 6.0 4.6
5.1 3.4 1.3 1.7 1.6 20 2.3 2.8 2.8 3.6 2.6 4.0 3.5 5.9 4.9 5.4 5.2 1.0 7.1 2.1 1.3 0.9 14 16 13 13 3.8 2.2 3.5 7.1 6.6 3.8 5.8 3.5 6.0 2.2 3.1 4.9 4.5 8.7
25 25 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – 13 – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
129 131 128 131 130 131 241 251 261 275 278 297 401 411 416 432 441 453 468 481 493 505 502 509 516 527 536 540 543 545 544 543 541 539 511 486 466 327 281 220
-345 -346 -354 -355 -360 -361 -358 -354 -347 -336 -337 -325 -225 -221 -220 -211 -206 -197 -189 -179 -171 -164 -171 -168 -165 -158 -155 -153 -153 -155 -160 -164 -169 -174 -204 -231 -254 -395 -443 -506
44 44 44 45 45 45 48 54 55 55 53 55 55 55 55 55 55 57 57 57 57 57 56 57 57 57 57 58 58 58 58 58 58 58 59 59 59 59 59 60

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?